玻璃体腔注射抗血管内皮生长因子药物治疗早产儿视网膜病变的研究现状_Chinese Journal of Ocular Fundus Diseases

Authors：

易佐慧子 ,  陈长征

430060 武汉大学人民医院眼科中心;

Corresponding author：

陈长征, Email: whuchenchzh@163.com

Keywords：

早产儿视网膜病/治疗; 抗体; 单克隆/药物作用; 抗体; 单克隆/投药和剂量; 综述

DOI：

10.3760/cma.j.issn.1005-1015.2014.01.030

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

与冷冻及激光光凝治疗比较,玻璃体腔注射抗血管内皮生长因子(VEGF)药物治疗早产儿视网膜病变(ROP)可减少对视网膜解剖结构的破坏,促使周边视网膜继续血管化,降低视网膜脱离、视野缺损及高度近视的发生。在ROP 1区病变及屈光间质混浊等激光光凝难以施行的患眼中有其独特优势。选择合理的药物和剂量,掌握最佳治疗时间,注意避免局部并发症及全身安全性等方面的问题,对进一步提高玻璃体腔注射抗VEGF药物治疗ROP的应用水平具有重要意义。

Citation： 易佐慧子, 陈长征. 玻璃体腔注射抗血管内皮生长因子药物治疗早产儿视网膜病变的研究现状. Chinese Journal of Ocular Fundus Diseases, 2014, 30(1): 103-106. doi: 10.3760/cma.j.issn.1005-1015.2014.01.030 Copy

1.	张国明.早产儿视网膜病变的治疗[M]//吴本清,黄丽娜,张国明.早产儿视网膜病变.广州:广东科技出版社,2007:37-108.
2.	Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity[J]. Curr Opin Pediatr, 2009, 21:182-187.
3.	Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors[J]. Early Hum Dev, 2012, 88:937-941.
4.	Chen J, Smith L. Retinopathy of prematurity[J]. Angiogenesis, 2007, 10:133-140.
5.	Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity:three-month outcome[J]. Arch Ophthalmol,1990, 108:195-204.
6.	Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity:results of the early treatment for retinopathy of prematurity randomized trial[J]. Arch Ophthalmol, 2003, 121:1684-1694.
7.	Flynn JT, Chan-Ling T. Retinopathy of prematurity:two distinct mechanisms that underlie zone 1 and zone 2 disease[J]. Am J Ophthalmol, 2006, 142:46-59.
8.	International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited[J]. Arch Ophthalmol, 2005, 123:991-999.
9.	Sun HJ, Choi KS, Lee SJ. Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity:a case report[J]. Jpn J Ophthalmol, 2012, 56:476-480.
10.	Mota A, Carneiro A, Breda J, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity[J]. Case Report Ophthalmol, 2012, 3:136-141.
11.	Spandau U, Tomic Z, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity[J]. Acta Ophthalmol, 2013, 91:170-175.
12.	Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity[J]. Indian J Ophthalmol, 2007, 55:75-76.
13.	Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity[J]. Retina, 2008, 28(Suppl 3):13-18.
14.	Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity[J]. Am J Ophthalmol, 2009, 148:536-543.
15.	Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3⁺ retinopathy of prematurity[J]. N Engl J Med, 2011, 364:603-615.
16.	Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan[J]. Am J Ophthalmol, 2013, 155:150-158.
17.	Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity[J]. J AAPOS, 2010, 14:2-3.
18.	Quiroz-Mercado H, Martinez-Castellanos M, Hernandez-Rojas M, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity[J]. Retina, 2008, 28(Suppl 3):19-25.
19.	Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246:1061-1063.
20.	Autrata R, Krejcírová I, Senková K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3⁺ retinopathy of prematurity in zone I and posterior zone Ⅱ[J]. Eur J Ophthalmol, 2012, 22:687-694.
21.	Autrata R, Senková K, Holousová M, et al. Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zoneⅠand posterior zone Ⅱ--four years results[J]. Cesk Slov Oftalmol, 2012, 68:29-36.
22.	Orozco-Gómez LP, Hernández-Salazar L, Moguel-Ancheita S, et al. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease:three years of experience[J]. Cir Cir, 2011, 79:207-214, 225-232.
23.	Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity:wrong dose, wrong drug, or both[J]. J AAPOS, 2012, 16:2-4.
24.	Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone Ⅰ retinopathy of prematurity[J]. Graefe's Arch Clin Exp Ophthalmol, 2007, 245:1727-1730.
25.	Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity:a morphologic study[J]. Arch Ophthalmol, 2008, 126:1161-1163.
26.	Martínez-Castellanos M, Schwartz S, Hernández-Rojas M, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up[J]. Retina, 2013, 33:329-338.
27.	Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes[J]. Invest Ophthalmol Vis Sci, 2010, 51:1606-1608.
28.	Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity[J]. Am J Ophthalmol, 2012, 153:327-333.
29.	Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity[J]. Acta Ophthalmol, 2013, 91:74-75.
30.	Hård AL, Hellstr m A.On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment--a review[J]. Acta Paediatr, 2011, 100:1523-1527.

1. 张国明.早产儿视网膜病变的治疗[M]//吴本清,黄丽娜,张国明.早产儿视网膜病变.广州:广东科技出版社,2007:37-108.
2. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity[J]. Curr Opin Pediatr, 2009, 21:182-187.
3. Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors[J]. Early Hum Dev, 2012, 88:937-941.
4. Chen J, Smith L. Retinopathy of prematurity[J]. Angiogenesis, 2007, 10:133-140.
5. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity:three-month outcome[J]. Arch Ophthalmol,1990, 108:195-204.
6. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity:results of the early treatment for retinopathy of prematurity randomized trial[J]. Arch Ophthalmol, 2003, 121:1684-1694.
7. Flynn JT, Chan-Ling T. Retinopathy of prematurity:two distinct mechanisms that underlie zone 1 and zone 2 disease[J]. Am J Ophthalmol, 2006, 142:46-59.
8. International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited[J]. Arch Ophthalmol, 2005, 123:991-999.
9. Sun HJ, Choi KS, Lee SJ. Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity:a case report[J]. Jpn J Ophthalmol, 2012, 56:476-480.
10. Mota A, Carneiro A, Breda J, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity[J]. Case Report Ophthalmol, 2012, 3:136-141.
11. Spandau U, Tomic Z, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity[J]. Acta Ophthalmol, 2013, 91:170-175.
12. Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity[J]. Indian J Ophthalmol, 2007, 55:75-76.
13. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity[J]. Retina, 2008, 28(Suppl 3):13-18.
14. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity[J]. Am J Ophthalmol, 2009, 148:536-543.
15. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3⁺ retinopathy of prematurity[J]. N Engl J Med, 2011, 364:603-615.
16. Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan[J]. Am J Ophthalmol, 2013, 155:150-158.
17. Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity[J]. J AAPOS, 2010, 14:2-3.
18. Quiroz-Mercado H, Martinez-Castellanos M, Hernandez-Rojas M, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity[J]. Retina, 2008, 28(Suppl 3):19-25.
19. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246:1061-1063.
20. Autrata R, Krejcírová I, Senková K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3⁺ retinopathy of prematurity in zone I and posterior zone Ⅱ[J]. Eur J Ophthalmol, 2012, 22:687-694.
21. Autrata R, Senková K, Holousová M, et al. Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zoneⅠand posterior zone Ⅱ--four years results[J]. Cesk Slov Oftalmol, 2012, 68:29-36.
22. Orozco-Gómez LP, Hernández-Salazar L, Moguel-Ancheita S, et al. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease:three years of experience[J]. Cir Cir, 2011, 79:207-214, 225-232.
23. Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity:wrong dose, wrong drug, or both[J]. J AAPOS, 2012, 16:2-4.
24. Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone Ⅰ retinopathy of prematurity[J]. Graefe's Arch Clin Exp Ophthalmol, 2007, 245:1727-1730.
25. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity:a morphologic study[J]. Arch Ophthalmol, 2008, 126:1161-1163.
26. Martínez-Castellanos M, Schwartz S, Hernández-Rojas M, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up[J]. Retina, 2013, 33:329-338.
27. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes[J]. Invest Ophthalmol Vis Sci, 2010, 51:1606-1608.
28. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity[J]. Am J Ophthalmol, 2012, 153:327-333.
29. Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity[J]. Acta Ophthalmol, 2013, 91:74-75.
30. Hård AL, Hellstr m A.On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment--a review[J]. Acta Paediatr, 2011, 100:1523-1527.

Previous Article
肾素-血管紧张素-醛固酮系统与早产儿视网膜病变
Next Article
感染和炎症与早产儿视网膜病变

Chinese Journal of Ocular Fundus Diseases

玻璃体腔注射抗血管内皮生长因子药物治疗早产儿视网膜病变的研究现状

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content